Abstract
PURPOSE: Pulmonary arterial hypertension (PAH) is a debilitating, progressive condition with diverse etiologies. Combining treatments that target different PAH disease pathways (prostacyclin; nitric oxide; endothelin) may be critical in reducing PAH morbidity. The purpose of this study was to evaluate the safety and efficacy of adding continuous intravenous (IV) or subcutaneous (SC) treprostinil sodium to existing therapy with a phosphodiesterase type 5 inhibitor (PDE5I), an endothelin receptor antagonist (ERA), or the combination of a PDE5I and ERA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
